What type of study is this?

This is a Phase 2 study (also classified as: Human Clinical Trial, Experimental Study).

September 29, 2025Cancer Research

Abstract B006: Exploiting Myeloid-Stromal IL1RAP as a Therapeutic Vulnerability to Improve Chemoimmunotherapy Sensitivity in Pancreatic Cancer

View Full Paper

Ask AI

Bookmark

Improved duration of response to anti-IL1RAP therapy in pancreatic cancer correlates with high myeloid-stromal expression.
Phase II study revealed a significant reduction in tumor volume and enhanced T-cell abundance with IL1RAP inhibition.
Navigating the tumor microenvironment by targeting IL1RAP could potentially restore T-cell function against pancreatic cancer.
Combining anti-IL1RAP therapy with standard chemotherapy prolongs survival in murine models, suggesting clinical relevance.

No takes yet. Share an insight, caveat, or question.

Phase II trial shows improved chemoimmunotherapy responses in pancreatic cancer patients, indicating IL1RAP as a potential target.

Marsh et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark